Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 142Observational 8Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Cancer Metastatic 1

Interventions

3-Iodobenzylguanidine 9Cyclophosphamide 6Amifampridine 6nilotinib 5fludarabine 5Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine phosphate 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × trifluridine tipiracil drug combination × Clear all
NCT02286492 2024-09-05

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Taiho Oncology, Inc.

Approved for marketing
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡